logo
The hidden physical powers that help women outlive men

The hidden physical powers that help women outlive men

CTV News07-07-2025
The female body is built for resilience and longevity, despite having more complex reproductive organs and often receiving fewer resources. Tatiana Maksimova/via CNN Newsource
People who lived through the Irish Potato Famine, enslavement in Trinidad and Icelandic measles epidemics all have something in common: Women outlive men in dire circumstances.
That's because the female body is built for resilience and longevity, as I found while researching for my new book, 'The Stronger Sex.'
Despite having more complex reproductive organs and the burdensome, sometimes fatal, functions that come with them — menstruation, pregnancy, childbirth and breastfeeding — female bodies tend to outlast male bodies. And that's the case even though girls in many parts of the world have access to fewer resources, such as food and medical care, than boys do.
That female toughness holds true in extreme circumstances, as Virginia Zarulli, now an associate professor of demography at Italy's University of Padua, found when she analyzed survival data across seven historical populations experiencing famines, epidemics and enslavement.
Under these brutal conditions, women outlived men across almost all ages and locations, including among the 'high-mortality' populations who confronted famine in Ukraine, Ireland and Sweden; enslavement in Trinidad; and measles epidemics in Iceland, according to her 2018 study, published in the journal PNAS. Even newborn girls in these environments had a higher survival rate than newborn boys — a hint that the female survival advantage is rooted in biology.
Essential female strength also shows up today in places where women experience fewer extreme physical stresses overall: 'When we analyze the empirical data, for modern people it shows that death rates for men are higher than for women, pretty much at every age,' Zarulli said.
Recognizing and building on these sex-based differences can help transform how we approach health care, including treatments for cancer and vaccine protocols — making medicine more precise, personalized and effective, especially for women.
Female chromosomes and hormones
People assigned female at birth have two X chromosomes, a fundamental advantage over XY, the chromosomes males have at birth. That's because the X chromosome is much larger, containing roughly 10 times more genes. Female bodies therefore have access to a wider range of immune genes, making their defense system remarkably strong and diverse. As neurogeneticist and evolutionary biologist Dr. Sharon Moalem wrote in 'The Better Half: On the Genetic Superiority of Women,' his book about the XX chromosome advantage, 'Women have immunologically evolved to out-mutate men.' Since viruses and bacteria are always mutating, an immune system that can quickly adapt is more resilient.
Estrogen, generally higher in female bodies, also confers a variety of immune advantages.
As a result, female mammals — including humans — have better-equipped immune systems, in both their innate, generalized responses and their adaptive, specialized responses. Female bodies also have higher counts of active neutrophils, the most common type of white blood cell that fights infections.
Scientists have also found that female bodies have more robust B cell activity — the action of white blood cells that adapt to fight off viruses or bacteria. This advantage may also be due in part to estrogen, and researchers are trying to tease apart what is mediated by hormones, what is affected by genes and what might be attributable to other causes.
Women produce more targeted antibodies to fight infections and also retain immunological memory longer, making their bodies more adept at responding to future infections, according to researchers. This all leads to 'the very well-known phenomenon that males tend to be more susceptible to a lot of diseases than females — though not in every disease or every individual, of course,' said Marlene Zuk, a Regents Professor and evolutionary biologist at the University of Minnesota in St. Paul.
Since female bodies mount stronger immune defenses, they generally have a stronger vaccine and virus response, a greater ability to fight off sepsis and a decreased risk of some cancers. The downside of this powerful system, however, is that women get more autoimmune diseases than men do. Women are also more likely to live with chronic illness after surviving diseases that would have killed male bodies.
The effect of testosterone
Testosterone also seems to be an immune disadvantage, and males have more of that hormone than females do. Zuk said that in early experiments scientists found they could 'neuter male animals and their immunity would get better or inject female animals with testosterone and their immunity would get worse.'
Why? It may be that the testosterone enables male animals toward greater reproductive success by 'living hard and dying young,' Zuk said. Some of the female immune advantage may be male immune disadvantage, and while it's accepted that hormones affect immunity, determining to what degree is an ongoing research question.
Physiology and culture
Some scientists argue that lifestyle and culture lead to a significant part of the male longevity disadvantage. As a population, men tend to smoke more, drink more alcohol and engage in riskier activities than women, and men tend to exclude most women from more physically dangerous jobs.
Studies focused on what happens when women adopt some of the unhealthy habits traditionally more likely among male populations, such as smoking, still show that women live longer than men, Zarulli said. 'In populations where men and women had the same lifestyle, there was still a difference in mortality — women had a higher life expectancy than men.'
The female advantage is likely due to more than genetic and hormonal factors, according to new research: It's also found in the very structure of women's bodies.
At North Carolina State University, a team led by microbial ecologist Erin McKenney and forensic anthropologist Amanda Hale conducted a landmark study measuring the lengths of the small intestines in cadavers for the first time since 1885.
The team discovered that women's small intestines were significantly longer than men's — an advantage that allows women to extract more nutrition from the same quantity of food.
This finding, published in the journal PeerJ in a 2023 paper, might be explained by the extra demands on female bodies throughout human history: 'The vast majority of the nutrients you need to replenish your system — especially during reproduction and nursing, like protein and fat — that's what's being absorbed by your small intestine,' Hale said.
This could be a key piece of the 'Female Buffering Hypothesis' — the idea that female biology evolved to withstand environmental and physiological stress better — according to Hale.
Traditional medical research has long ignored the complexities of the female body. As these genomic and physiological functions are better studied and understood, the drivers behind the strength and resilience of the female body will come into focus. This knowledge will inform more targeted treatments for infection and immunity—for all bodies.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Man survives several days in B.C. wilderness by 'slurping pond water' and eating 'whatever he could find'
Man survives several days in B.C. wilderness by 'slurping pond water' and eating 'whatever he could find'

National Post

time2 days ago

  • National Post

Man survives several days in B.C. wilderness by 'slurping pond water' and eating 'whatever he could find'

Article content Williams Lake RCMP say 39-year-old Andrew Barber was 'slurping pond water' and 'munched on whatever he could find' to stay alive for several days after his truck had broken down in a remote part of the Cariboo. Article content Staff Sgt. Brad McKinnon says Barber was first reported missing on July 31, and found him on Aug. 8 on forest service past McLeese Lake after an RCMP helicopter had spotted him by his self-made shelter near a rock with the word 'Help' written on it. Article content Article content Article content McKinnon says police officers found Barber with an injured right leg and 'severely dehydrated' before taking him by air to Cariboo Memorial Hospital in Williams Lake, from which he has since been released. Article content Article content McKinnon says he has been told that Barber is 'doing quite well' after his experience, but adds that the outcome 'likely could have been very different' given Barber's lack of clean drinking water. Article content

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

National Post

time5 days ago

  • National Post

Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Article content Article content Article content the United States, Europe, the United Kingdom, and Australia – Article content – European CTA approval to initiate the EMBRACE study in Ireland, Poland, and Greece has been received – Article content – Recently received Medicines and Healthcare products Regulatory Agency ('MHRA') approval to commence EMBRACE in the United Kingdom – Article content – Data from completed Phase 2 MDD study showed that 71% of participants were in remission and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003 – Article content TORONTO — Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative next-generation treatment options, today announced that its Clinical Trial Application ('CTA') has been approved by the Irish Medicines Board, acting as the reference Member state, to initiate the EMBRACE ™ study in Ireland, Poland, and Greece. EMBRACE is the second pivotal study in PARADIGM ®, the Company's Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The Company also recently announced approval from the Medical and Healthcare products Regulatory Agency ('MHRA') to commence EMBRACE in the United Kingdom. Article content CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration ('FDA') for the adjunctive treatment of Major Depressive Disorder ('MDD'). Article content 'Securing European approval to commence the EMBRACE component of PARADIGM – especially on the heels of the recent UK MHRA approval – validates the quality of our Phase 3 clinical development program and reaffirms the strength of our results to date,' said Doug Drysdale, Chief Executive Officer of Cybin. 'We appreciate the trust placed in us by the European Regulatory Agencies and are eager to leverage Europe's well-established clinical trial infrastructure. The EMBRACE study aims to enroll 330 participants who live with moderate to severe MDD and whose symptoms are inadequately controlled with antidepressant treatments. With this additional approval, which enables us to enroll participants in Ireland, Poland, and Greece, we are pleased to expand the reach for this critical research. The rise in mental health disorders knows no borders, and we are committed to an international research base to develop new and more effective treatments for MDD patients everywhere.' Article content Study Design: Article content EMBRACE will enroll 330 patients with moderate to severe MDD (MADRS≥24) who are on a stable dose of antidepressant medication but are responding inadequately. Study participants will be randomized 1:1:1 to receive either CYB003 16 mg, CYB003 8 mg, or inactive placebo. Each study arm will evaluate two doses, administered three weeks apart. The primary endpoint will be change in depressive symptoms as measured by change in MADRS from baseline at six weeks after the first dose. Article content The Phase 3 PARADIGM™ program is expected to enroll a total of 550 participants across three studies: two 12-week randomized, double-blind, placebo-controlled studies, APPROACH™ and EMBRACE, and a long-term extension study, EXTEND. The first Phase 3 trial, APPROACH, is currently dosing and is taking place at approximately 45 clinical sites across the U.S, and patient rollover into EXTEND is ongoing. The second Phase 3 trial, EMBRACE, is expected to enroll participants at approximately 60 clinical sites across the U.S., Europe, and Australia. Participants from APPROACH and EMBRACE will have the opportunity to roll over into EXTEND after completing the 12-week, double-blind, placebo-controlled treatment periods. Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release relating to the Company are forward-looking statements or forward-looking information within the meaning of applicable securities laws (collectively, 'forward-looking statements') and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'potential', 'possible', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the Company's plans to enroll participants and add additional clinical sites for the PARADIGM program; the Company's plan to enroll 330 participants at 60 clinical sites across the United States, Europe, United Kingdom and Australia for the EMBRACE study; and the Company's plans to engineer proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health conditions. APPROACH and EMBRACE are registered trademarks of Cybin IRL Limited, a subsidiary of Cybin. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the year ended March 31, 2025 and the Company's annual information form for the year ended March 31, 2025, which are available under the Company's profile on SEDAR+ at and with the U.S. Securities and Exchange Commission on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Contacts Article content Investor & Media: Article content Article content Gabriel Fahel Article content Article content Chief Legal Officer Article content Article content Cybin Inc. Article content Article content Article content Article content

Medtronic to announce financial results for its first quarter of fiscal year 2026
Medtronic to announce financial results for its first quarter of fiscal year 2026

Globe and Mail

time7 days ago

  • Globe and Mail

Medtronic to announce financial results for its first quarter of fiscal year 2026

GALWAYIreland , /CNW/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, August 19, 2025 , for its first quarter of fiscal year 2026, which ended on Friday, July 25, 2025 , A news release containing summary financial information will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at A video webcast to discuss results will begin at 7:00 a.m. CDT and can be accessed at Within 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at Looking ahead, Medtronic plans to report its fiscal year 2026 second, third, and fourth quarter results on Tuesday, November 18, 2025 , February 17, 2026 , and Wednesday, May 20, 2026 , respectively. Confirmation and additional details will be provided closer to the specific event. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit and follow Medtronic on LinkedIn. Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. Contacts: Public Relations +1-763-526-8478 Ryan Weispfenning Investor Relations +1-763-505-4626 View original content to download multimedia: SOURCE Medtronic plc

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store